Beijing Foyou Pharma (601089.SH) has obtained the approval notice for the listing application of the raw material kelevoron.

Beijing Foyou Pharma (601089.SH) announced that the company has recently received the approval issued by the National Medical Products Administration for the raw material drug Klietolol, "Chemical Raw Material Drug Market Application Approval Notice". Klietolol is used for the topical treatment of mild to moderate atopic dermatitis patients aged 2 and above. This approval will further enrich the company's product line and promote the company's continuous, stable, and healthy development.